These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26513538)

  • 1. Advances in the pharmacologic treatment of ventricular arrhythmias.
    Schleifer JW; Sorajja D; Shen WK
    Expert Opin Pharmacother; 2015; 16(17):2637-51. PubMed ID: 26513538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
    Lazzara R
    Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.
    AbdelWahab A; Sapp J
    Curr Cardiol Rep; 2017 Sep; 19(11):105. PubMed ID: 28900864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A perspective on the ESVEM trial current knowledge: sotalol should not be the first-line agent in the management of ventricular arrhythmias.
    Garan H
    Prog Cardiovasc Dis; 1996; 38(6):455-6. PubMed ID: 8638026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-arrhythmia agents in the therapy of ventricular arrhythmias in the post-CAST era].
    Candinas R; Bauersfeld U
    Schweiz Med Wochenschr; 1994 Sep; 124(35):1545-9. PubMed ID: 7939521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical therapy to prevent recurrence of ventricular arrhythmia in normal and structural heart disease patients.
    Jacobson JT; Iwai S; Aronow W
    Expert Rev Cardiovasc Ther; 2016 Nov; 14(11):1251-1262. PubMed ID: 27494263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choice and chance in drug therapy of cardiac arrhythmias: technique versus drug-specific responses in evaluation of efficacy.
    Singh BN
    Am J Cardiol; 1993 Nov; 72(16):114F-124F. PubMed ID: 8237824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of beta blockade in the therapy of serious ventricular arrhythmias.
    Reiter MJ; Reiffel JA
    Am J Cardiol; 1998 Aug; 82(4A):9I-19I. PubMed ID: 9737650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute management of ventricular arrhythmias: role of antiarrhythmic agents.
    Singh BN
    Pharmacotherapy; 1997; 17(2 Pt 2):56S-64S; discussion 89S-91S. PubMed ID: 9085341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Class III drugs and congestive heart failure: focus on the congestive heart failure-survival trial of antiarrhythmic therapy.
    Singh SN; Fletcher RD
    Am J Cardiol; 1999 Nov; 84(9A):103R-108R. PubMed ID: 10568668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia.
    Pokorney SD; Mi X; Hammill BG; Allen LaPointe NM; Curtis LH; Al-Khatib SM
    Am J Cardiol; 2017 May; 119(9):1401-1406. PubMed ID: 28341360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of determination of QT dispersal intervals in anti-arrhythmia therapy].
    Konecná P; Dvorák R; Semrád B
    Vnitr Lek; 1999 Aug; 45(8):453-6. PubMed ID: 11045143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of the Electrophysiologic Study versus Electrocardiographic Monitoring trial for controlling ventricular tachycardia and fibrillation.
    Reiffel JA
    Am J Cardiol; 1996 Aug; 78(4A):34-40. PubMed ID: 8780327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Class III antiarrhythmic agents: the next wave.
    Bauman JL
    Pharmacotherapy; 1997; 17(2 Pt 2):76S-83S; discussion 89S-91S. PubMed ID: 9085343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-blockers for ventricular arrhythmias: have we underestimated their value?
    Campbell TJ
    Aust N Z J Med; 1996 Oct; 26(5):689-96. PubMed ID: 8958366
    [No Abstract]   [Full Text] [Related]  

  • 19. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
    Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators
    N Engl J Med; 1997 Nov; 337(22):1576-83. PubMed ID: 9411221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parenteral antiarrhythmic drug therapy in ventricular tachycardia/ventricular fibrillation: evolving role of class III agents--focus on amiodarone.
    Scheinman MM
    J Cardiovasc Electrophysiol; 1995 Oct; 6(10 Pt 2):914-9. PubMed ID: 8548112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.